Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction , makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized tumor therapies.
- The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction , makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized tumor therapies.
- The authors of the ‘Comment’ are all researchers affiliated with the DECOD-Ag consortium of which Achilles Therapeutics is a member.
- Co-author Dr Sergio Quezada, Chief Scientific Officer of Achilles, commented: “Accurate prediction of neoantigen immunogenicity can be pivotal in determining the efficacy of immunological treatments.
- It is therefore essential that we collaborate to refine our prediction models and improve the precision of our T cell therapies.”